Added to YB: 2026-03-05
Pitch date: 2026-03-03
RNA [neutral]
Avidity Biosciences, Inc.
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs).
Market Cap
$11.3B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-13.14
P/E
-14.65
EV/Sales
514.55
Sector
Biotechnology
Category
special_situation
Show full summary:
KEDM Lite Vol. 4 - Atrium Therapeutics (RNA US)
RNA (update): Early-stage precision cardiology spin from Avidity/Novartis deal. Two lead programs targeting rare genetic heart diseases, both pre-IND. $270M cash, no near-term financing risk. Clinical milestones years away. Small spin vs Avidity in weak markets—monitor price action.
Read full article (1 min)